Biopharma data showed M&A strength, selective venture capital favoring Phase II, record obesity deals, and significant ...

As the conference approaches, scientists are reviewing new technologies that enhance manufacturing process control, product ...

Advanced biotech equipment, driven by R&D investment and personalized medicine, is essential for scalable drug production and ...

This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development ...

M&A favors late-stage assets, obesity deals surge, AI accelerates manufacturing, and policy drives strategic US facility investment.

ICE Pharma will present its bile acid-derived innovations and sustainability strategies at CPHI Frankfurt 2025. The company's ...

AstraZeneca’s $4.5 billion investment in Virginia expands its US drug manufacturing footprint, creating 3600 jobs and ...

At the Cell and Gene Meeting on the Mesa, a panel discussion was held on advanced therapy production and how it demands ...

The EU's life science strategy aims to enhance public health, create jobs, and foster innovation by 2030, positioning the EU ...

The new label for prefilled syringes, in conjunction with innovations from SCHOTT Pharma, enables integrated tamper-evidence ...

The awarded $1.7 million in funding will support the company’s preclinical and clinical progress on DMX-1001 (noribogaine), ...

Data from four major pivotal trials will be shared, but AstraZeneca medications and pipeline molecules appear in more than 90 abstracts for the upcoming conference in Berlin.